Navigation Links
Roche Acquires RALS IT Connectivity Assets to Strengthen Presence in Point-of-Care Information Management
Date:10/13/2010

INDIANAPOLIS, Oct. 13 /PRNewswire-FirstCall/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) and Medical Automation Systems, Inc. (MAS) announced today that they have signed an agreement under which Roche will acquire certain assets from MAS, a Charlottesville, Virginia-based privately held company. Under the terms of the agreement, Roche will acquire all the assets associated with the RALS point-of-care (POC) information technology (IT) connectivity system, as well as the names "Medical Automation Systems," "MAS" and "RALS." As part of the transaction, Roche expects to retain substantially all of the MAS employees.

"As a global leader in POC testing, Roche is committed to helping improve the quality of patient care by providing products that support clinical decision-making," said Jack Phillips, president and CEO of Roche Diagnostics Corporation North America. "Information management plays an increasingly critical role to meet the growing needs of our POC customers. With this acquisition, we will build on our strategy to deliver integrated testing solutions to our customers."

MAS is the market leader in POC information management with the RALS POC IT connectivity system, used in over 2,000 hospitals in the United States (USA). MAS pioneered the use of IT systems to improve the efficiency and regulatory compliance of hospital POC programs. Over the past decade, MAS has consistently brought innovative functionality to the market through collaborative development with its diagnostic partners.  

"MAS and Roche have had a close partnership for over ten years to co-market RALS for hospital blood glucose testing in the US" said Kurt Wassenaar, chief executive officer of MAS. "Roche is the ideal company to build upon the RALS system and deliver the next generation of information management systems. We're very pleased that Roche has decided to acquire these assets and is committed to ensuring the continued success and support of the RALS products and pipeline."

Roche Diagnostics develops and commercializes innovative solutions in the field of serum-based laboratory and POC testing, including CoaguChek® and ACCU-CHEK® brand products used by healthcare professionals to monitor coagulation and blood glucose at the point of care. They are currently used with the RALS information management systems in healthcare facilities across the US.

"The acquisition of RALS assets is a perfect fit with our strategy to deliver market-leading IT connectivity solutions. It further complements our IT product portfolio," stated Peter Finckh, Head of Global Platforms and Support Roche Diagnostics. "With this acquisition, we gain a very talented group of people with strong expertise and domain knowledge in POC IT, which we expect to be instrumental in delivering future generations of POC -IT solutions in collaboration with existing forces. It will further enable our mission to provide leading integrated testing solutions for our customers."

As part of Roche, RALS will remain a vendor-neutral IT connectivity solution and Roche will continue to expand the number of device interfaces available, enabling customers to streamline POC management in their hospitals.  

This transaction is subject to customary closing conditions. Upon closing, the legal entity currently known as MAS will be renamed.

About MASMAS, a leading provider of POC information management systems, is based in Charlottesville, Virginia, USA.  In addition to the RALS system, MAS provides informatics solutions for critical care applications including inpatient IV insulin dosing software and ICU outcomes reporting software, as well as analytical services.  

About RocheHeadquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2009, Roche had over 80,000 employees worldwide and invested almost 10 billion Swiss francs in R&D. The Group posted sales of 49.1 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com or www.roche-diagnostics.us.

All trademarks used or mentioned in this release are protected by law.For further information, please contact: Betsy CoxDirector, Corporate CommunicationsRoche Diagnostics CorporationIndianapolis, IN(317) 521-3911betsy.cox@roche.com
'/>"/>

SOURCE Roche Diagnostics Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
2. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
3. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
4. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
5. Roche Announces Positive Results in Solid Tumors Using Human Monoclonal Antibody Against IGF-1R (R1507)
6. Roche Diagnostics HIV Viral Load Test Used in Clinical Trials for Isentress, a New Class of HIV Drug
7. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
8. Two Pivotal Phase III Studies for Roches ACTEMRA(TM) (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms
9. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
10. Roche responds to announcement of IDEAL hepatitis C trial results
11. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... 2016  Sequent Medical, Inc. announced today that it ... the safety and effectiveness of the WEB™ Aneurysm Embolization ... aneurysms.  Prof Laurent Spelle , MD, Head of ... France and Principal Investigator of the CLARYS ... and Germany.  Although patients with ruptured aneurysms ...
(Date:2/12/2016)... and SEOUL, South Korea ... Biosys­tems Menarini and Macrogen, Inc. today announced they ... and innovative procedures for precision medicine in cancer. ... Silicon Biosystems, DEPArray™ digital-sorting technology with Macrogen,s high-throughput ... tests certified under the Clinical Laboratory Improvement Amendments ...
(Date:2/12/2016)... MILTON, Ontario , Feb. 12, 2016  Aralez ... specialty pharmaceutical company, today announced the Company will ring the ... Square, New York at 4:00 ... the formation of Aralez. Adrian Adams ... will be held 3:50 to 4:00 p.m. ET.  A ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... 2016 , ... The law firm of Morrow, Morrow, Ryan & Bassett is ... these scholarships is to encourage applicants to pursue a degree in their field of ... parishes. , “We have available jobs in St. Landry and Evangeline Parishes that ...
(Date:2/12/2016)... ... February 12, 2016 , ... CDRH Enforcement Trends: , Back to the Future , ... , As Winston Churchill said, “Those who don’t learn from history are doomed to ... expect when they come knocking this year. But that takes time. , Take a ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... As a ... hectic schedule, a demanding job, and no time to decompress, Rabinowitz found herself drawn ... herself to meditation for its impact on her life, implementing a 20-minute-per-day meditation practice ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... at Zuckerberg San Francisco General Hospital on April 5-7. The series is a ... create new habits. The workshops cover a broad range of topics, including coaching ...
(Date:2/12/2016)... ... , ... Fisher House Foundation Chairman and CEO Kenneth Fisher joined Governor Brian ... president Scott Bensing, and Peggy Kearns Director, VA Southern Nevada Healthcare System yesterday to ... will be the first Fisher House in Nevada, and will provide free lodging for ...
Breaking Medicine News(10 mins):